Qiagen (QGEN) Set to Announce Earnings on Monday

Qiagen (NYSE:QGEN) will issue its quarterly earnings data after the market closes on Monday, April 29th. Analysts expect the company to announce earnings of $0.44 per share for the quarter. Qiagen has set its FY 2024 guidance at 2.100- EPS.Parties interested in registering for the company’s conference call can do so using this link.

Qiagen (NYSE:QGEN) last posted its earnings results on Tuesday, February 6th. The company reported $0.55 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.55. The business had revenue of $509.00 million during the quarter, compared to analyst estimates of $500.77 million. Qiagen had a return on equity of 12.99% and a net margin of 17.37%. During the same quarter in the previous year, the firm earned $0.53 EPS. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Stock Up 1.4 %

QGEN stock opened at $41.65 on Friday. The company has a quick ratio of 1.62, a current ratio of 1.99 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $9.50 billion, a PE ratio of 27.53, a PEG ratio of 3.47 and a beta of 0.41. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.70. The stock has a 50-day simple moving average of $42.58 and a two-hundred day simple moving average of $42.66.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on QGEN shares. JPMorgan Chase & Co. lifted their price target on Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, February 8th. Morgan Stanley upgraded Qiagen from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $49.48 to $51.00 in a research report on Friday, February 16th. Finally, Citigroup dropped their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.69.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.